Breakthrough in Prostate Cancer Treatment: Combination Therapy Shows Significant Benefits

Researchers at AstraZeneca have made a groundbreaking discovery in the treatment of prostate cancer, revealing that a combination of poly(ADP-ribose) polymerase inhibitors (PARPi) with androgen receptor (AR) pathway inhibitors (ARPi) can significantly improve outcomes for patients with metastatic, castration-resistant prostate cancer. This study, published in NAR Cancer, found that the combination of ARPi and PARPi showed benefits in both patients with tumors harbouring mutations in homologous recombination repair (HRR) genes and those without such alterations.

Key Takeaways:

• The combination of PARPi and ARPi in metastatic, castration-resistant prostate cancer patients showed significant benefits, with improved outcomes observed in both patients with and without HRR mutations.
• The research found that the benefit of the combination therapy was driven by an increase in DNA double-strand breaks and micronuclei formation, which was not due to a control of HRR gene transcription by the AR.
• A novel role of PARP1 modulating AR recruitment to chromatin in the presence of DNA damage was also uncovered.
• The study provided a mechanism-of-action consistent with the clinical benefit of the combination of PARPi and ARPi in patients with prostate cancer.
• Financial supporters for the research included the John Black Charitable Foundation, AstraZeneca UK, Cancer Research UK, and the Prostate Cancer Foundation.

Statistics:

• The study found that the combination of PARPi and ARPi showed benefits in both patients with and without HRR mutations, indicating a broad applicability of the treatment.
• The research revealed a novel role of PARP1 modulating AR recruitment to chromatin in the presence of DNA damage, providing a new mechanism-of-action for the combination therapy.
• The study highlighted the importance of understanding the interplay between PARP1 and AR in dealing with genotoxic insults.

Sources:

• NewsRx. Researchers at AstraZeneca Report New Data on Prostate Cancer (Androgen receptor inhibition extends PARP inhibitor activity in prostate cancer models beyond BRCA mutations and defects in homologous recombination repair). Cancer Weekly. October 21, 2025; p 126.
• NAR Cancer. Androgen receptor inhibition extends PARP inhibitor activity in prostate cancer models beyond BRCA mutations and defects in homologous recombination repair, 2025;7(4).
• AstraZeneca. Bioscience, Oncology R&D, AstraZeneca, Francis Crick Avenue, Cambridge CB2 0AA, UK.